PTC Therapeutics (PTCT) Stock Price, Quote, News & History | Benzinga

PTC Therapeutics Inc (PTCT) Stock Price, Quote, News & History

PTCTNASDAQ

Trade with Public

Trade with Public

$71.70

-0.27-0.38%

At close: Aug 14, 5:00 PM EST

$71.70

N/A

After Hours: 4:00 PM EST

M&A: Sangamo Therapeutics announced it will sell assets to PTC Therapeutics (PTCT) on Wednesday, August 12, 2026

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$71.58

Close

$71.70

Volume / Avg.

564.33K / 1.69M

Day Range

$70.85 - $72.13

52 Wk Range

45.43 - 90.87

Market Cap

$5.98B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

17.16%

Days to Cover

7.52

Recent PTC Therapeutics, Inc. News

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.

Vandana Singh

Top 3 Health Care Stocks You'll Regret Missing This Quarter

The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold players in this sector.

Avi Kapoor

PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers

PTC Therapeutics stock drops after PIVOT-HD update, as FDA approval doubts offset dose-based benefits and stable safety signals.

Vandana Singh

PTC Therapeutics Pulls Translarna Bid After FDA Flags Weak Proof

PTC Therapeutics, Inc. (PTCT) stock closed lower following the withdrawal of its New Drug Application for Translarna by the FDA.

Vandana Singh

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-30.50M

Investing Cash Flow (TTM)

-471.91M

Financing Cash Flow (TTM)

536.00M

Free Cash Flow (TTM)

-332.56M

Capital Expenditure (TTM)

-302.05M

Net Change in Cash (TTM)

33.59M

Analyst Trends and Forecast

3

May

1

Jun

4

Jul

2

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.4

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$4.45B

PE Ratio (TTM)

-

PE Ratio (FWD)

39.84

PEG Ratio (TTM)

-

PS Ratio (TTM)

6.49

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-0.93%

Earnings Yield % (FWD)

2.51%

EV / EBITDA (TTM)

25.78

Price / EBITDA (TTM)

37.73

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.98

Company Debt

Total Debt

$590.97M

LT Debt

$535.52M

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$342.38M

Total Cash

$1.05B

Debt to Equity

-

Issuance of Debt (TTM)

$207.62M

Repayment of Debt (TTM)

-$342.38M

Key Statistics

Open

$71.58

Close

$71.70

Volume / Avg.

564.33K / 1.69M

Day Range

$70.85 - $72.13

52 Wk Range

45.43 - 90.87

Market Cap

$5.98B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

41

Short Interest

17.16%

Days to Cover

7.52

About

Sector

Health Care

Industry

Biotechnology

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that in...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy PTC Therapeutics (PTCT) stock?

A

You can purchase shares of PTC Therapeutics (NASDAQ:PTCT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are PTC Therapeutics (PTCT) competitors?

A

Other companies in PTC Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for PTC Therapeutics (PTCT) stock?

A

PTC Therapeutics has a consensus price target of $83.84.

Q

What is the current price for PTC Therapeutics (PTCT)?

A

The stock price for PTC Therapeutics (NASDAQ: PTCT) is $71.7 last updated August 14, 2026 at 4:00 PM EDT.

Q

Does PTC Therapeutics (PTCT) pay a dividend?

A

There are no upcoming dividends for PTC Therapeutics.

Q

When is PTC Therapeutics (NASDAQ:PTCT) reporting earnings?

A

PTC Therapeutics does not have any upcoming earnings scheduled.

Q

Is PTC Therapeutics (PTCT) going to split?

A

There is no upcoming split for PTC Therapeutics.

Q

What sector and industry does PTC Therapeutics (PTCT) operate in?

A

PTC Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.